Ahead of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reporting second-quarter financial results tomorrow, before market open, Canaccord analyst Neil Maruoka keeps in mind the …
Canaccord analyst Neil Maruoka expressed a cautious stance today on drug maker AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), after the company reported fourth-quarter financial results that were below …
Canaccord analyst Neil Maruoka weighed in today with his views on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), as the company will report unaudited fourth-quarter financial results on …
Canaccord’s healthcare analyst Neil Maruoka weighed in on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the company announced the finalization of a co-promotion agreement …
Canaccord analyst Neil Maruoka weighed in with a few insights on AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), following the completion of share consolidation at a conversion ratio of 100-to-1, …
Canaccord’s healthcare analyst Neil Maruoka weighed in today with his views on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), following a bear report by Citron Research implying that …
In a research report released Monday, Canaccord analyst Neil Maruoka maintained a Hold rating on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and reduced the price target to …
Canaccord Genuity analyst Neil Maruoka came out with his views on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), after the company provided updated guidance on its planned registration …
In a research report released today, Canaccord Genuity analyst Neil Maruoka reiterated a Hold rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) with a $0.
Canaccord Genuity analyst Neil Maruoka came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), reducing the price target to $0.
